2023, Volume 25, Issue 5
Strategic Study of CAE >> 2023, Volume 25, Issue 5 doi: 10.15302/J-SSCAE-2023.05.003
Analysis and Prospect of the Pharmaceutical Industry Development Trend in China
1. Institute of Medical Innovation Research, Peking University Third Hospital, Beijing 100191, China;
2. Subject Construction Office, Peking University Health Science Center, Beijing 100191, China;
3. Institute of Advanced Clinical Medicine, Beijing 100191, China
Next Previous
Abstract
The pharmaceutical industry is vital for safeguarding people’s lives and health. This study is based on a macro perspective and provides a comprehensive and in-depth comparison regarding the development trends of the pharmaceutical industry in China and abroad. It is pointed out that the global market size and strategic position of the pharmaceutical industry in various countries are constantly improving. Meanwhile, the development prospects of China’s pharmaceutical industry are broad, and the potential market space is large. On this basis, we further review and explore the driving factors behind the stable and rapid development of China’s pharmaceutical industry in recent years, which include demographic changes, global economic instability, and continuous investment from innovative entities such as governments and enterprises. Moreover, from the perspective of patients, we propose the challenges faced by the pharmaceutical industry in five aspects: precision, safety, timeliness, affordability, and policy guarantee. Furthermore, targeted policy recommendations are proposed to focus on building and maintaining a refined large-scale population cohort and data platform, sorting out China’s cutting-edge technology fields, promoting the industrialization of pharmaceutical research and development, improving multi-level medical security channels, and enhance the full chain of policy protection and the implementation efficiency, thus to provide a reference for subsequent investment, policy formulation, and development decisions for China’s pharmaceutical industry.
Keywords
pharmaceutical industry ; pharmaceutical research and development ; priority strategies ; drivers ; full chain guarantee
Figures
图1
References
[ 1 ] IQVIA.The global use of medicines 2023 [R/OL]. [2023-02-15].https://www.iqvia.com/fr-fr/library/presentations/the-global-use-of-medicines-2023. link1
[ 2 ] NIH. Proposed adcanced research prohects agency for health [EB/OL]. (2021-08-11)[2023-08-10]. https://www.nibib.nih.gov/arpa-h-listening-session. link1
[ 3 ] Collins F S, Schwetz T, Tabak L A, et al. ARPA-H: Accelerating biomedical breakthroughs [J]. Science, 2021, 373(6551): 165‒167.
[ 4 ]
马晓玲 . 美国建设生物医药创新高地的实践及对我国的启示 [J]. 中国科学院院刊 , 2023 , 38 2 : 294 ‒ 301 .
Ma X L . The practice of building biopharmaceutical innovation heights in the United States and its enlightenment for China [J]. Journal of the Chinese Academy of Sciences , 2023 , 38 2 : 294 ‒ 301 .
[ 5 ] The White House Office of Science and Technology Policy. Bold goals for U.S. biotechnology and biomanufacturing [EB/OL]. (2023-03)[2023-08-10]. https://www.whitehouse.gov/wp-content/uploads/2023/03/Bold-Goals-for-U.S.-Biotechnology-and-Biomanufacturing-Harnessing-Research-and-Development-To-Further-Societal-Goals-FINAL.pdf. link1
[ 6 ]
董兰军 . 日本生物技术产业创新发展分析 [J]. 高科技与产业化 , 2021 , 27 10 : 46 ‒ 48 .
Dong L J . Analysis of innovation and development in Japan´s biotechnology industry [J]. High-Technology and Industrialization , 2021 , 27 10 : 46 ‒ 48 .
[ 7 ]
康捷 , 袁永 , 胡海鹏 . 英国生物医药产业创新发展现状、经验及启示 [J]. 特区经济 , 2022 8 : 46 ‒ 49 .
Kang J , Yuan Y , Hu H P . The current situation, experience and inspiration of innovative development in the UK biopharmaceutical industry [J]. Special Zone Economy , 2022 8 : 46 ‒ 49 .
[ 8 ] Government HM. Industrial strategy: Life sciences sector deal 2 [EB/OL]. [2023-08-10]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/761588/life-sciences-sector-deal-2-web-ready-version.pdf. link1
[ 9 ] The Lancet Oncology. UK pharmaceutical industry under threat [J]. The Lancet Oncology, 2014, 15(7): 667.
[10]
李洁 , Qian D . NHS制度背景下英国医药产业政策体系探析与启示 [J]. 中国卫生事业管理 , 2016 , 33 11 : 806 ‒ 843 .
Li J , Qian D . Analysis and enlightenment on the policy system of the UK pharmaceutical industry under the background of NHS system [J]. China´s Health Administration , 2016 , 33 11 : 806 ‒ 843 .
[11] Nationale Bioökonomiestrategie für eine nachhaltige, kreislauforientierte und starke Wirtschaft. Pressemitteilung des BMBF vom 15.01.2020, Nr.003/2020 [EB/OL]. (2020-01-15)[2023-08-10]. https://www.bmbf.de/bmbf/shareddocs/pressemitteilungen/de/nationale-biooekonomiestrategi-entierte-und-starke-wirtschaft.html. link1
[12] GTAI. The pharmaceutical industry in Germany [EB/OL]. [2021-01-27][2023-02-15]. https://www.gtai.de/en/invest/industries/healthcare-market-germany/pharmaceutical-industry. link1
[13]
中华人民共和国全国人民代表大会 . 中华人民共和国国民经济和社会发展第十四个五年规划和2035年远景目标纲要 [EBOL]. 2021-03-16 [ 2023-08-10 ]. http:www.gov.cnxinwen2021-0313content_5592681.htm .
The National People´s Congress of the PRC . Outline of The 14th Five Year Plan 2021 — 2025 for national economic and social development and vision 2035 of the People´s Republic of China [EBOL]. 2021-03-16 [ 2023-08-10 ]. http:www.gov.cnxinwen2021-0313content_5592681.htm .
link1
[14]
中华人民共和国工业和信息化部 . “十四五”医药工业发展规划 [EBOL]. 2022-07-06 [ 2023-08-10 ]. https:www.miit.gov.cn .
Ministry of Industry and Information Technology of the People´s Republic of China . The 14th Five Year Plan for the development of the pharmaceutical industry [EBOL]. 2022-07-06 [ 2023-08-10 ]. https:www.miit.gov.cn .
link1
[15]
正略咨询 . 医药制造行业2023年度蓝皮书 [EBOL]. 2021-03-16 [ 2023-08-10 ]. https:m.163.comdyarticleHUIVL8J80538CYKL.html .
Consulting Zhenglue . 2023 blue book for the pharmaceutical manufacturing industry [EBOL]. 2021-03-16 [ 2023-08-10 ]. https:m.163.comdyarticleHUIVL8J80538CYKL.html .
link1
[16]
国家统计局 . 第七次人口普查主要数据 [EBOL]. 2023-04-21 [ 2023-08-10 ]. http:www.stats.gov.cn .
National Bureau of Statistics . Main data of the seventh population census [EBOL]. 2023-04-21 [ 2023-08-10 ]. http:www.stats.gov.cn .
link1
[17]
美国制药经理人 . 2023全球药企排名TOP50 [EBOL]. 2023-06-19 [ 2023-08-10 ]. https:baijiahao.baidu.coms?id=176911810018890 4634wfr=spiderfor=pc .
Executive Pharmaceutical . 2023 top 50 global pharmaceutical companies ranking [EBOL]. 2023-06-19 [ 2023-08-10 ]. https:baijiahao.baidu.coms?id=1769118100188904634wfr=spiderfor=pc .
link1
[18]
中国医药创新促进会 , 中国外商投资企业协会药品研制和开发行业委员会 . 构建中国医药创新生态系统系列报告第一篇: 2015—2020年发展回顾及未来展望 [R]. 北京 : 中国医药创新促进会, 中国外商投资企业协会药品研制和开发行业委员会 , 2021 .
China Pharmaceutical Innovation Promotion Association, China Association of Foreign Investment Enterprises Pharmaceutical Research and Development Industry Committee RDPAC . Building a Chinese medical innovation ecosystem series report part 1: Development review and future prospects from 2015 to 2020 [R]. Beijing : China Pharmaceutical Innovation Promotion Association, China Association of Foreign Investment Enterprises Pharmaceutical Research and Development Industry Committee RDPAC , 2021 .
[19]
国家统计局 . 健康产业统计分类 2019 [EBOL]. 2019-04-01 [ 2023-08-10 ]. https:www.gov.cngongbaocontent2019content_5421550.htm .
National Bureau of Statistics . Classification of health industry statistics 2019 [EBOL]. 2019-04-01 [ 2023-08-10 ]. https:www.gov.cngongbaocontent2019content_5421550.htm .
link1
京公网安备 11010502051620号
